"Lymphoma, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
| Descriptor ID |
D016399
|
| MeSH Number(s) |
C04.557.386.480.750 C15.604.515.569.480.750 C20.683.515.761.480.750
|
| Concept/Terms |
Lymphoma, T-Cell- Lymphoma, T-Cell
- Lymphoma, T Cell
- T-Cell Lymphoma
- Lymphomas, T-Cell
- T Cell Lymphoma
- T-Cell Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell".
This graph shows the total number of publications written about "Lymphoma, T-Cell" by people in this website by year, and whether "Lymphoma, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell" by people in Profiles.
-
Nguyen PN, Tran NTB, Nguyen TPX, Ngo TNM, Lai DV, Deel CD, Hassell LA, Vuong HG. Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):431-438.
-
Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020 09 08; 4(17):4256-4266.
-
Cochran D, Cook G, Rensing A, Frimberger D, Meenakshi-Sundaram B. A Rare Case of T-Cell Lymphoma Presenting With Bilateral Nephrolithiasis and Acute Renal Failure. Urology. 2020 12; 146:222-224.
-
Simões IT, Aranda F, Casadó-Llombart S, Velasco-de Andrés M, Català C, Álvarez P, Consuegra-Fernández M, Orta-Mascaró M, Merino R, Merino J, Alberola-Ila J, González-Aseguinolaza G, Carreras E, Martínez V, Lozano F. Multifaceted effects of soluble human CD6 in experimental cancer models. J Immunother Cancer. 2020 03; 8(1).
-
Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.
-
Magro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol. 2018 Jul; 35(4):247-259.
-
Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN. Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol. 2010 Aug; 63(2):292-308.
-
Briggs JH, Algan O, Stea B. Primary T-cell lymphoma of the breast: a case report. Cancer Invest. 2003; 21(1):68-72.